The "me-better" biotech Eagle Pharmaceuticals has filed an S-1 with the SEC outlining plans to raise $50 million through an IPO. The Woodcliff Lake, NJ-based company tweaks existing injectable drugs to make them preferable to the original therapies and says it is working on 6 advanced development programs with two approved products. Its two most advanced development projects (EP-3101 and 3102) are focused on Teva's ($TEVA) Treanda, which is used to treat hematologic cancers. The biotech plans to list under the "EGRX" symbol. S-1